<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To estimate the direct medical costs of hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by the level of <z:hpo ids='HP_0000093'>proteinuria</z:hpo> and to evaluate the differences between patients whose <z:hpo ids='HP_0000112'>nephropathy</z:hpo> did and did not progress </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: We identified 7,758 patients with <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> who had a urine albumin-to-<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio (UACR) during 2001-2003 and at least one follow-up UACR 3-5 years later </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were followed for up to 8 years for progression of <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, which was defined by increasing levels of <z:hpo ids='HP_0000093'>proteinuria</z:hpo>: normoalbuminuria (UACR &lt; 30 mg/g), <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (30-299 mg/g), macroalbuminuria (â‰¥300 mg/g), and <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (dialysis or transplant) </plain></SENT>
<SENT sid="3" pm="."><plain>We calculated annualized inpatient, outpatient, pharmaceutical, and total medical costs incurred by patients after the baseline measure through 2008, comparing patients who did and did not progress to a higher <z:hpo ids='HP_0000112'>nephropathy</z:hpo> stage </plain></SENT>
<SENT sid="4" pm="."><plain>We also compared pre- and postprogression costs among those whose <z:hpo ids='HP_0000112'>nephropathy</z:hpo> progressed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Patients with normoalbuminuria who progressed to <z:mp ids='MP_0002959'>microalbuminuria</z:mp> experienced an annualized change in baseline costs that was $396 higher (P &lt; 0.001) than those who maintained <z:mpath ids='MPATH_458'>normal</z:mpath> <z:mp ids='MP_0002871'>albuminuria</z:mp> ($902 vs. $506) </plain></SENT>
<SENT sid="6" pm="."><plain>Among those with <z:mp ids='MP_0002959'>microalbuminuria</z:mp>, progression was significantly associated with a $747 difference (P &lt; 0.001) in annualized change in outpatient costs compared with no progression ($1,056 vs. $309) </plain></SENT>
<SENT sid="7" pm="."><plain>Among patients who progressed, costs were 37% higher following progression from normoalbuminuria to <z:mp ids='MP_0002959'>microalbuminuria</z:mp> ($10,188 vs. $7,424; P &lt; 0.001), and 41% higher following progression from <z:mp ids='MP_0002959'>microalbuminuria</z:mp> to macroalbuminuria ($12,371 vs. $8,753; P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Progression of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> was strongly associated with higher subsequent medical care costs in hypertensive patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Greater prevention efforts may reduce the substantial economic burden of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>